# ProMIS Neurosciences Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/fi/companies/ProMIS Neurosciences Inc.). ## Overview ProMIS Neurosciences Inc. is a U.S.-based biopharmaceutical company developing antibody therapies and therapeutic vaccines for neurodegenerative and other protein-misfolding diseases. Its research platform uses protein biology, physics, and supercomputing to identify disease-specific epitopes and design selective therapeutics and diagnostics, with a focus on Alzheimer’s disease, multiple system atrophy, and ALS. ## Products & services • Antibody therapies for neurodegenerative diseases • Therapeutic vaccines targeting misfolded proteins • Protein-misfolding discovery platform • Disease-specific epitope identification and validation • Preclinical and clinical development programs - **Antibody therapeutics** (40%) — Selective antibodies designed to target toxic misfolded proteins in neurodegenerative disease. - **Therapeutic vaccines** (25%) — Vaccine candidates intended to generate immune responses against disease-specific protein conformations. - **Discovery platform** (20%) — Computational and protein-biology tools used to identify disease-specific epitopes and candidates. - **Diagnostics research** (10%) — Research efforts aimed at detecting toxic misfolded proteins for disease identification. - **Collaborative licensing potential** (5%) — Potential future value from collaborations, licenses, or strategic transactions. - Antibody therapies for neurodegenerative diseases - Therapeutic vaccines targeting misfolded proteins - Protein-misfolding discovery platform - Disease-specific epitope identification and validation - Preclinical and clinical development programs ## Customers ProMIS does not sell commercial products today; its near-term counterparties are research partners, clinical investigators, regulators, and potential licensing or collaboration partners. If its programs advance, the eventual customers would be healthcare providers and patients in specialty neurology markets, but the business model is still centered on development-stage value creation rather than product sales. - **Pharmaceutical collaboration partners** (primary) — Potential partners that may license assets, fund development, or co-develop programs. - **Clinical investigators and trial sites** (primary) — Hospitals and research centers that enroll patients and generate clinical data for PMN310 and other programs. - **Regulatory agencies** (secondary) — Agencies that review safety, biomarker, and efficacy data before any approval path. - **Future neurology patients** (emerging) — Patients with Alzheimer’s disease, MSA, ALS, and other protein-misfolding disorders. - Clinical trial sites and investigators running neurology studies - Regulators reviewing preclinical and clinical data packages - Potential pharma partners for licensing or collaboration - Future specialty neurology prescribers and treatment centers - Patients with Alzheimer’s, MSA, ALS, and related disorders ## Geography ProMIS is headquartered in the United States and its disclosures are presented in U.S. dollars. Its development work is organized around clinical and research activities rather than a manufacturing footprint, so geography mainly reflects where trials, collaborators, and capital markets are located. - Headquartered in the United States - Financial reporting and cash balances are in U.S. dollars - Clinical and research activity is centered on neurology programs - Geography is driven by trial sites and partner locations, not sales - No country-level revenue disclosed because the company has no revenue ## Strategy ProMIS is focused on advancing its lead Alzheimer’s program PMN310 while continuing to build a pipeline across other protein-misfolding diseases. Its strategy depends on progressing preclinical and clinical work, refining biomarker and trial design, and securing external funding or partnerships to support development. - **Advance PMN310 clinical development** (short-term) — The lead Alzheimer’s asset is central to the company’s value creation and partnering potential. - **Broaden the pipeline across protein-misfolding diseases** (medium-term) — A broader portfolio can reduce single-asset dependence and expand partnering options. - **Secure non-dilutive or dilutive funding** (short-term) — Development-stage biotech requires ongoing capital to fund trials and regulatory work. - Advance PMN310 as the lead Alzheimer’s program - Develop additional assets such as PMN267 and PMN442 - Use biomarker and trial-design optimization to improve development - Pursue collaborations, licensing, or strategic transactions - Raise capital to fund research, clinical testing, and regulatory work ## Risks The company faces the typical risks of development-stage biotechnology, including clinical failure, regulatory setbacks, and the need for substantial external funding. Its disclosures also highlight going-concern uncertainty and a material weakness in internal control over financial reporting, both of which can affect execution and investor confidence. - **Funding shortfall** [critical] — The company has no revenue and needs additional capital to continue development and operations. - **Clinical development failure** [high] — Drug candidates may not show sufficient safety or efficacy in preclinical or clinical studies. - **Going-concern uncertainty** [critical] — Management disclosed substantial doubt about the ability to continue as a going concern. - **Internal control weakness** [high] — A material weakness can delay reliable reporting and undermine investor confidence. - **Regulatory and commercialization risk** [high] — Even successful candidates require approvals, manufacturing readiness, and market access. - No product revenue and dependence on future financing - Clinical and preclinical programs may fail or be delayed - Regulatory approval is uncertain and time-consuming - Going-concern risk if capital is not raised on time - Material weakness in internal control over financial reporting ## Accounting As a pre-revenue biotech, ProMIS’s reported results are driven mainly by research and development accruals, clinical study costs, and share-based compensation rather than revenue recognition. Investors should also watch estimates around R&D accruals, financing-related equity issuance, and any future impairment or valuation judgments as the pipeline advances. - **Research and development accruals** — Affects operating expenses and liabilities - **Share-based compensation** — Affects operating loss and equity - **Going-concern assessment** — Affects financial statement presentation and risk perception - **Equity financing accounting** — Affects equity balances and financing cash flow presentation - No revenue recognized since inception - R&D accrual estimates affect expense timing - Clinical and CRO costs are expensed as incurred - Share-based compensation can materially affect operating loss - Going-concern disclosures affect financial statement interpretation --- *Last updated: 2026-04-29T04:49:40.505588+00:00*